中美盆腔炎性疾病的诊治规范对比解读

doi:10.20047/j.issn1673-7210.2023.03.20

Abstract
Figure/Table
References (26)
Related Citation (15)

Download: PDF (647 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Pelvic inflammatory disease (PID) is one of the common diseases of women of childbearing age, which can lead to sequelae such as tubal infertility, ectopic pregnancy, and chronic pelvic pain, and cause great harm to female reproductive health. In 2021, the Centers for Disease Control and Prevention (CDC) issued Sexually Transmitted Infections Treatment Guidelines, 2021 (“2021 CDC guidelines” for short), completing a significant update to Sexually Transmitted Diseases Treatment Guidelines, 2015 (“2015 CDC guidelines” for short), most of the symptoms and signs of PID are mild or latent, so the diagnosis still relies on the minimum clinical standards. The treatment is mainly based on the use of broad spectrum, empirical antibiotics covering all possible pathogens, emphasizing the addition of metronidazole to cover anaerobic bacteria. Different intravenous and non-intravenous drug regimens have shown good efficacy. This paper compares the 2021 CDC guidelines, 2015 CDC guidelines, and Chinese Guidelines for Diagnosis and Treatment of Pelvic Inflammatory Diseases (2019 Revision), in order to provide reference and help for the current clinical practice of PID in China.

Key words： Pelvic inflammatory disease Diagnosis Treatment Guideline

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LI Ting LIU Zhaohui

Cite this article:

LI Ting LIU Zhaohui. Contrastive interpretation of diagnosis and treatment norms of pelvic inflammatory diseases in China and the United States[J]. 中国医药导报, 2023, 20(3): 88-92.

URL:

https://www.yiyaodaobao.com.cn/EN/10.20047/j.issn1673-7210.2023.03.20 OR https://www.yiyaodaobao.com.cn/EN/Y2023/V20/I3/88

[1] Savaris RF，Fuhrich DG，Maissiat J，et al. Antibiotic therapy for pelvic inflammatory disease[J]. Cochrane Database Syst Rev，2020，8（8）：CD010285.
[2] Kreisel KM，Llata E，Haderxhanaj L，et al. The Burden of and Trends in Pelvic Inflammatory Disease in the United States，2006-2016 [J]. J Infect Dis，2021，224（12 Suppl 2）：S103-S112.
[3] Workowski KA，Bachmann LH，Chan PA，et al. Sexually Transmitted Infections Treatment Guidelines，2021 [J]. MMWR Recomm Rep，2021，70（4）：1-187.
[4] Workowski KA，Bolan GA. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines，2015 [J]. MMWR Recomm Rep，2015，64（33）：924.
[5] 中华医学会妇产科学分会感染性疾病协作组.盆腔炎症性疾病诊治规范（2019修订版）[J].中华妇产科杂志，2019， 54（7）：433-437.
[6] Soper DE. Pelvic inflammatory disease [J]. Obstet Gynecol，2010，116（2 Pt 1）：419-428.
[7] Causer L，Liu B，Watts C，et al. Hospitalisations for pelvic inflammatory disease in young Aboriginal women living in remote Australia：the role of chlamydia and gonorrhoea [J]. Sex Transm Infect，2022，98（6）：445-447.
[8] Yagur Y，Weitzner O，Barchilon Tiosano L，et al. Characteristics of pelvic inflammatory disease caused by sexually transmitted disease - An epidemiologic study [J]. J Gynecol Obstet Hum Reprod，2021，50（9）：102176.
[9] Wiesenfeld HC，Meyn LA，Darville T，et al. A randomized controlled trial of ceftriaxone and doxycycline，with or without metronidazole，for the treatment of acute pelvic inflammatory disease [J]. Clin Infect Dis，2021，72：1181-1189.
[10] 刘朝晖，廖秦平.盆腔炎性疾病致病微生物及治疗方案研究[J].实用妇产科杂志，2010，26（7）：522-524.
[11] 张展，刘朝晖.盆腔炎性疾病的诊治进展[J].中国实用妇科与产科杂志，2019，35（4）：473-477.
[12] Brun JL，Castan B，de Barbeyrac B，et al. Pelvic inflammatory diseases：Updated French guidelines [J]. J Gynecol Obstet Hum Reprod，2020，49（5）：101714.
[13] Brunham RC，Gottlieb SL，Paavonen J. Pelvic inflammatory disease [J]. N Engl J Med，2015，372（21）：2039-2048.
[14] Gottesman T，Yossepowitch O，Samra Z，et al. Prevalence of Mycoplasma genitalium in men with urethritis and in high risk asymptomatic males in Tel Aviv：a prospective study [J]. Int J STD AIDS，2017，28：127-132.
[15] 张岱.盆腔炎的诊治进展[J].临床药物治疗杂志，2019， 17（12）：36-39，69.
[16] Kim HJ，Park JK，Park SC，et al. The prevalence of causative organisms of community-acquired urethritis in an age group at high risk for sexually transmitted infections in Korean soldiers [J]. J R Army Med Corps，2017，163（1）：20-22.
[17] Libois A，Hallin M，Crucitti T，et al. Prevalence of Mycoplasma genitalium in men with urethritis in a large public hospital in Brussels，Belgium：an observational，cross-sectional study [J]. PLoS One，2018，13（4）：e0196217.
[18] Ness RB，Kip KE，Hillier SL，et al. A cluster analysis of bacterial vaginosis-associated microflora and pelvic inflammatory disease [J]. Am J Epidemiol，2005，162（6）：585-590.
[19] Haggerty CL，Totten PA，Tang G，et al. Identification of novel microbes associated with pelvic inflammatory disease and infertility [J]. Sex Transm Infect，2016，92（6）：441-446.
[20] Ness RB，Hillier SL，Kip KE，et al. Bacterial vaginosis and risk of pelvic inflammatory disease [J]. Obstet Gynecol，2004， 104（4）：761-769.
[21] Savaris RF，Fuhrich DG，Duarte RV，et al. Antibiotic therapy for pelvic inflammatory disease: an abridged version of a Cochrane systematic review and meta-analysis of randomised controlled trials [J]. Sex Transm Infect，2019，95（1）：21-27.
[22] St Cyr S，Barbee L，Workowski KA，et al. Update to CDC’s Treatment Guidelines for Gonococcal Infection，2020 [J]. MMWR Morb Mortal Wkly Rep，2020，69（50）：1911-1916.
[23] Day MJ，Spiteri G，Jacobsson S，et al. Stably high azithromycin resistance and decreasing ceftriaxone susceptibility in Neisseria gonorrhoeae in 25 European countries，2016 [J]. BMC Infect Dis，2018，18（1）：609.
[24] Gernert KM，Seby S，Schmerer MW，et al. Azithromycin susceptibility of Neisseria gonorrhoeae in the USA in 2017：a genomic analysis of surveillance data [J]. Lancet Microbe，2020，1（4）：e154-e164.
[25] Dean G，Soni S，Pitt R，et al. Treatment of mild-to-moderate pelvic inflammatory disease with a short-course azith- romycin-based regimen versus ofloxacin plus metronidazole：results of a multicentre，randomised controlled trial [J]. Sex Transm Infect，97（3）：177-182.
[26] 中华中医药学会.中医药单用/联合抗生素治疗常见感染性疾病临床实践指南盆腔炎性疾病：T/CACM 010-2017[S]. 北京：中国中医药出版社，2016.